Addressing Canada’s Pharmaceutical Research and Development Intensity Gap: The Role of Health Data Transformation.
The life sciences industry, and specifically the pharmaceutical sub-sector, is a major funder of private sector research and development. Canada’s life sciences industry reinvests less of its revenues in research and development (R&D) activities than those in peer countries, which hinders innovation...
| Publicado en: | Healthcare Quarterly Vol. 29; no. 2; pp. 29 - 37 |
|---|---|
| Autores principales: | , |
| Formato: | tables/charts Journal Article |
| Publicado: |
Longwoods Publishing
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196866583&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196866583 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17102774 162E jtl: Healthcare Quarterly issn: 17102774 maglogo: N pubinfo: dt: Jul2026 vid: 29 iid: 2 pid: 20495 pub: Longwoods Publishing place: Toronto, Ontario artinfo: ui: 196866583 196866583 196866583 196866583 ppf: 29 ppct: 8 formats: tig: atl: Addressing Canada’s Pharmaceutical Research and Development Intensity Gap: The Role of Health Data Transformation. aug: au: Mullie, Thomas Chuck, Anderson affil: Health economist at Acute Care Alberta, Calgary, AB. sug: subj: Pharmaceutical Companies Canada Research, Medical Economics, Pharmaceutical Technology, Pharmaceutical Health Information Investments Health Care Industry Canada Private Sector Diffusion of Innovation Healthcare Supply Chain Productivity Financing, Government ab: The life sciences industry, and specifically the pharmaceutical sub-sector, is a major funder of private sector research and development. Canada’s life sciences industry reinvests less of its revenues in research and development (R&D) activities than those in peer countries, which hinders innovation, creates supply risks and contributes to Canada’s poor productivity growth. Traditional approaches to incentivizing reinvestment, including tax incentives, direct funding and public research spending, have failed. As an alternative, transforming Canada’s health data systems would enable faster and more comprehensive secondary use, making R&D investments safer and more productive. Our peers are already pursuing this strategy, meaning Canada risks being left behind unless we act. pubtype: Trade Publication doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|